|
1
|
Siegel RL, Kratzer TB, Wagle NS, Sung H
and Jemal A: Cancer statistics, 2026. CA Cancer J Clin.
76:e700432026.PubMed/NCBI
|
|
2
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Derakhshan F and Reis-Filho JS:
Pathogenesis of triple-negative breast cancer. Annu Rev Pathol.
17:181–204. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer; Cham: 2017
|
|
5
|
Korde LA, Somerfield MR, Carey LA, Crews
JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, et
al: Neoadjuvant chemotherapy, endocrine therapy, and targeted
therapy for breast cancer: ASCO guideline. J Clin Oncol.
39:1485–1505. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmid P, Cortes J, Dent R, McArthur H,
Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, et al:
Overall survival with pembrolizumab in early-stage triple-negative
breast cancer. N Engl J Med. 391:1981–1991. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schmid P, Cortés J, Dent R, Pusztai L,
McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, et al:
Event-free survival with pembrolizumab in early triple-negative
breast cancer. N Engl J Med. 386:556–567. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shah M, Osgood CL, Amatya AK, Fiero MH,
Pierce WF, Nair A, Herz J, Robertson KJ, Mixter BD, Tang S, et al:
FDA approval summary: Pembrolizumab for neoadjuvant and adjuvant
treatment of patients with high-risk early-stage triple negative
breast cancer. Clin Cancer Res. 28:5249–5253. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Korde LA, Somerfield MR and Hershman DL;
Neoadjuvant Chemotherapy, : Endocrine Therapy, Targeted Therapy for
Breast Cancer Guideline Expert Panel: Use of immune checkpoint
inhibitor pembrolizumab in the treatment of high-risk, early-stage
triple-negative breast cancer: ASCO guideline rapid recommendation
update. J Clin Oncol. 40:1696–1698. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li J, Hao C, Wang K, Zhang J, Chen J, Liu
Y, Nie J, Yan M, Liu Q, Geng C, et al: Chinese Society of Clinical
Oncology (CSCO) Breast Cancer guidelines 2024. Transl Breast Cancer
Res. 5:182024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Curigliano G, Burstein HJ, Gnant M, Loibl
S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP and
Thürlimann B; St Gallen Consensus Conference Panelists 2023, :
Understanding breast cancer complexity to improve patient outcomes:
The St. Gallen International consensus conference for the primary
therapy of individuals with early breast cancer 2023. Ann Oncol.
34:970–986. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dixon-Douglas J, Loibl S, Denkert C, Telli
M and Loi S: Integrating immunotherapy into the treatment landscape
for patients with triple-negative breast cancer. Am Soc Clin Oncol
Educ Book. 42:1–13. 2022.PubMed/NCBI
|
|
13
|
Liu Z, Li J, Zhao F, Ren D, Li Z, Chen Y,
Huang S, Liu Z, Zhao Y, Wang M, et al: Long-term survival after
neoadjuvant therapy for triple-negative breast cancer under
different treatment regimens: A systematic review and network
meta-analysis. BMC Cancer. 24:4402024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tarantino P, Corti C, Schmid P, Cortes J,
Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F and
Curigliano G: Immunotherapy for early triple negative breast
cancer: Research agenda for the next decade. NPJ Breast Cancer.
8:232022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adamo B and Anders CK: Stratifying
triple-negative breast cancer: Which definition(s) to use? Breast
Cancer Res. 13:1052011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pusztai L, Denkert C, O'Shaughnessy J,
Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, et
al: Event-free survival by residual cancer burden with
pembrolizumab in early-stage TNBC: Exploratory analysis from
KEYNOTE-522. Ann Oncol. 35:429–436. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song F, Tarantino P, Garrido-Castro A,
Lynce F, Tolaney SM and Schlam I: Immunotherapy for early-stage
triple negative breast cancer: Is earlier better? Curr Oncol Rep.
26:21–33. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kolberg-Liedtke C, Feuerhake F, Garke M,
Christgen M, Kates R, Grischke EM, Forstbauer H, Braun M, Warm M,
Hackmann J, et al: Impact of stromal tumor-infiltrating lymphocytes
(sTILs) on response to neoadjuvant chemotherapy in triple-negative
early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Res.
24:582022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Llop-Guevara A, Loibl S, Villacampa G,
Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A,
Jank P, van Mackelenbergh M, et al: Association of RAD51 with
homologous recombination deficiency (HRD) and clinical outcomes in
untreated triple-negative breast cancer (TNBC): Analysis of the
GeparSixto randomized clinical trial. Ann Oncol. 32:1590–1596.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arnaud E, Vaflard P, Escalup L, Ramtohul
T, Meziani D, Thibault L, Desmaris RP, Feron JG, Pierga JY, Cabel
L, et al: Treatment toxicities and pathological response through
the evolution of neoadjuvant regimens in early triple-negative
breast cancer. ESMO Real World Data Digit Oncol. 9:1001572025.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rached L, Peyre-Pradat F, Spotti M,
Baldini C, Laparra A, Lambotte O, Sakkal M, Perret A, Viansone A,
Michiels S, et al: Real-world safety and effectiveness of
neoadjuvant chemotherapy combination with pembrolizumab in
triple-negative breast cancer. ESMO Real World Data Digit Oncol.
5:1000612024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Andrade MO, Gutierres IG, Tavares MC, de
Sousa IM, Balint FC, Marin Comini AC, Gouveia MC, Bines J, Madasi
F, Ferreira RDP, et al: Immune-related adverse events among
patients with early-stage triple-negative breast cancer treated
with pembrolizumab plus chemotherapy: Real-world data from the
Neo-Real/GBECAM 0123 study. Breast. 83:1044732025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krishnan J, Patel A, Roy AM, Alharbi M,
Kapoor A, Yao S, Khoury T, Hong CC, Held N, Chakraborty A, et al:
Detrimental impact of chemotherapy dose reduction or
discontinuation in early stage triple-negative breast cancer
treated with pembrolizumab and neoadjuvant chemotherapy: A
multicenter experience. Clin Breast Cancer. 24:e701–e711.e2. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES,
Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant
capecitabine for breast cancer after preoperative chemotherapy. N
Engl J Med. 376:2147–2159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tutt ANJ, Garber JE, Kaufman B, Viale G,
Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A,
Balmaña J, et al: Adjuvant olaparib for patients with BRCA1- or
BRCA2-mutated breast cancer. N Engl J Med. 384:2394–2405. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Geyer CE Jr, Garber JE, Gelber RD, Yothers
G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, et al:
Overall survival in the OlympiA phase III trial of adjuvant
olaparib in patients with germline pathogenic variants in BRCA1/2
and high-risk, early breast cancer. Ann Oncol. 33:1250–1268. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shaitelman SF, Tereffe W, Dogan BE, Hess
KR, Caudle AS, Valero V, Stauder MC, Krishnamurthy S, Candelaria
RP, Strom EA, et al: Role of ultrasonography of regional nodal
basins in staging triple-negative breast cancer and implications
for local-regional treatment. Int J Radiat Oncol Biol Phys.
93:102–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim D, Kim JH, Kim IA, Chang JH and Shin
KH: Impact of postmastectomy radiation therapy on breast cancer
patients according to pathologic nodal status after modern
neoadjuvant chemotherapy. Cancer Res Treat. 55:592–602. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Zhang Y, Liu Z, Qin Z, Li Y, Zhao
J, Ma X, Yang Q, Han N, Zeng X, et al: Impact of postmastectomy
radiotherapy on locoregional control and disease-free survival in
patients with breast cancer treated with neoadjuvant chemotherapy.
J Oncol. 2021:66326352021.PubMed/NCBI
|
|
30
|
Chen X, Xia F, Luo J, Ma J, Yang Z, Zhang
L, Feng Y, Shao Z, Yu X and Guo X: Postmastectomy radiotherapy
reduces locoregional and disease recurrence in patients with stage
II–III triple-negative breast cancer treated with neoadjuvant
chemotherapy and mastectomy. Onco Targets Ther. 11:1973–1980. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mamounas EP, Bandos H, White JR, Julian
TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA,
McCloskey SA, et al: Omitting regional nodal irradiation after
response to neoadjuvant chemotherapy. N Engl J Med. 392:2113–2124.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adrada BE, Candelaria R, Moulder S,
Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L,
Scoggins ME, et al: Early ultrasound evaluation identifies
excellent responders to neoadjuvant systemic therapy among patients
with triple-negative breast cancer. Cancer. 127:2880–2887. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gupta S, Nair N, Hawaldar RW, Joshi S,
Gulia S, Shet T, Sarin R, Parmar V, Desai S, Ghosh J, et al:
Addition of carboplatin to sequential taxane-anthracycline
neoadjuvant chemotherapy in triple-negative breast cancer: A phase
III randomized controlled trial. J Clin Oncol. 44:9–19. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Pádua Souza C, Carneiro ASB, de
Oliveira Lessa AC, Lacerda DC, Paiva CE, Zorzetto MMC, de Freitas
AJA, Santana IVV, de Oliveira MA, Palmero EI, et al: Neoadjuvant
carboplatin in triple-negative breast cancer: Results from
NACATRINE, a randomized phase II clinical trial. Breast Cancer Res
Treat. 202:57–65. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sikov WM, Berry DA, Perou CM, Singh B,
Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER,
et al: Impact of the addition of carboplatin and/or bevacizumab to
neoadjuvant once-per-week paclitaxel followed by dose-dense
doxorubicin and cyclophosphamide on pathologic complete response
rates in stage II to III triple-negative breast cancer: CALGB 40603
(Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shepherd JH, Ballman K, Polley MC,
Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS,
Hoadley KA, Hu Z, et al: CALGB 40603 (Alliance): Long-term outcomes
and genomic correlates of response and survival after neoadjuvant
chemotherapy with or without carboplatin and bevacizumab in
triple-negative breast cancer. J Clin Oncol. 40:1323–1334. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mason SRE, Willson ML, Egger SJ, Beith J,
Dear RF and Goodwin A: Platinum chemotherapy for early
triple-negative breast cancer. Breast. 75:1037122024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Geyer CE, Sikov WM, Huober J, Rugo HS,
Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP,
et al: Long-term efficacy and safety of addition of carboplatin
with or without veliparib to standard neoadjuvant chemotherapy in
triple-negative breast cancer: 4-year follow-up data from
BrighTNess, a randomized phase III trial. Ann Oncol. 33:384–394.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sharma P, Stecklein SR, Yoder R, Staley
JM, Schwensen K, O'Dea A, Nye L, Satelli D, Crane G, Madan R, et
al: Clinical and biomarker findings of neoadjuvant pembrolizumab
and carboplatin plus docetaxel in triple-negative breast cancer:
NeoPACT phase 2 clinical trial. JAMA Oncol. 10:227–235. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zdenkowski N, Kuper-Hommel MJJ, Niman SM,
Francis PA, Baron-Hay S, Fox W, Menzies AM, Angus R, Punie K,
Zardawi S, et al: Timing of nivolumab with neoadjuvant carboplatin
and paclitaxel for early triple-negative breast cancer
(BCT1902/IBCSG 61–20; Neo-N): A non-comparative, open-label,
randomized phase 2 trial. Lancet Oncol. 26:367–377. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gluz O, Nitz U, Kolberg-Liedtke C, Prat A,
Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L,
et al: De-escalated neoadjuvant chemotherapy in early
triple-negative breast cancer (TNBC): Impact of molecular markers
and final survival analysis of the WSG-ADAPT-TN trial. Clin Cancer
Res. 28:4995–5003. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Spring LM, Tolaney SM, Fell G, Bossuyt V,
Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, et
al: Response-guided neoadjuvant sacituzumab govitecan for localized
triple-negative breast cancer: Results from the NeoSTAR trial. Ann
Oncol. 35:293–301. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
McArthur HL, Tolaney SM, Dent R, Schmid P,
Asselah J, Liu Q, Meisel JL, Niikura N, Park YH, Werutsky G, et al:
TROPION-Breast04: A randomized phase III study of neoadjuvant
datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by
adjuvant durvalumab versus standard of care in patients with
treatment-naïve early-stage triple negative or HR-low/HER2-negative
breast cancer. Ther Adv Med Oncol. 17:175883592513161762025.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bardia A, Pusztai L, Albain K, Ciruelos
EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, et
al: TROPION-Breast03: A randomized phase III global trial of
datopotamab deruxtecan ± durvalumab in patients with
triple-negative breast cancer and residual invasive disease at
surgical resection after neoadjuvant therapy. Ther Adv Med Oncol.
16:175883592412483362024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bonadio RC, de Sousa IM, Balint FC, Comini
ACM, Tavares MC, Madasi F, Bines J, Ferreira RDP, Rosa DD, Santos
CL, et al: Dose dense versus 3 weekly AC during neoadjuvant
chemoimmunotherapy for triple negative breast cancer. NPJ Breast
Cancer. 10:1122024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sharma P, Kimler BF, O'Dea A, Nye L, Wang
YY, Yoder R, Staley JM, Prochaska L, Wagner J, Amin AL, et al:
Randomized phase II trial of anthracycline-free and
anthracycline-containing neoadjuvant carboplatin chemotherapy
regimens in stage I–III triple-negative breast cancer (NeoSTOP).
Clin Cancer Res. 27:975–982. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Du Y and Huang L: Efficacy and safety of
platinum-based, anthracycline-free neoadjuvant chemotherapy for
triple-negative breast cancer: A systematic review and
meta-analysis. Discov Oncol. 16:15672025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wei Y, Li Q, Mo H, Qi Y, Ge H, Sun X, Fan
Y, Zhang P, Wang J, Luo Y, et al: Comparative efficacy of
anthracycline-free and anthracycline-containing neoadjuvant
chemoimmunotherapy regimens for triple-negative breast cancer.
Transl Oncol. 51:1021712025. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiao D, Qiao J, Sun X, Wang C, Lu Z, Zhang
C, Li L, Yan M, Feng Y, Zhou Y, et al: Application of neoadjuvant
docetaxel plus cisplatin in early-stage triple-negative breast
cancer (HELEN-001): Results from a phase II trial. Clin Cancer Res.
31:2589–2598. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Abraham JE, Pinilla K, Dayimu A, Grybowicz
L, Demiris N, Harvey C, Drewett LM, Lucey R, Fulton A, Roberts AN,
et al: The PARTNER trial of neoadjuvant olaparib with chemotherapy
in triple-negative breast cancer. Nature. 629:1142–1148. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mittendorf EA, Zhang H, Harbeck N, Zhang
H, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, et al:
Peri-operative atezolizumab in early-stage triple-negative breast
cancer: Final results and ctDNA analyses from the randomized phase
3 IMpassion031 trial. Nat Med. 31:2397–2404. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mittendorf EA, Zhang H, Barrios CH, Saji
S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al:
Neoadjuvant atezolizumab in combination with sequential
nab-paclitaxel and anthracycline-based chemotherapy versus placebo
and chemotherapy in patients with early-stage triple-negative
breast cancer (IMpassion031): A randomised, double-blind, phase 3
trial. Lancet. 396:1090–1100. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gianni L, Huang CS, Egle D, Bermejo B,
Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, et
al: Pathologic complete response (pCR) to neoadjuvant treatment
with or without atezolizumab in triple-negative, early high-risk
and locally advanced breast cancer: NeoTRIP Michelangelo randomized
study. Ann Oncol. 33:534–543. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gianni L, Huang C, Egle D, Bermejo B,
Zamagni C, Thill M, Anton Torres A, Bianchini G, Sevillano
Fernandez E, et al: LBA19 Event-free survival (EFS) analysis of
neoadjuvant taxane/carboplatin with or without atezolizumab
followed by an adjuvant anthracycline regimen in high-risk triple
negative breast cancer (TNBC): NeoTRIP Michelangelo randomized
study. Ann Oncol. 34 (Suppl 2):S1258–S1259. 2023. View Article : Google Scholar
|
|
55
|
Chen L, Li H, Zhang H, Yang H, Qian J, Li
Z, Ren Y, Wang S, Fu P, Yang H, et al: Camrelizumab vs placebo in
combination with chemotherapy as neoadjuvant treatment in patients
with early or locally advanced triple-negative breast cancer: The
camrelief randomized clinical trial. JAMA. 333:673–681. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nederlof I, Isaeva OI, de Graaf M, Gielen
RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH,
Mandjes IAM, et al: Neoadjuvant nivolumab or nivolumab plus
ipilimumab in early-stage triple-negative breast cancer: A phase 2
adaptive trial. Nat Med. 30:3223–3235. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kolberg HC, Schumacher J, Erber R, Braun
M, Fasching PA, Grischke EM, Schem C, Lux MP, Deryal M, Hoffmann O,
et al: Atezolizumab monotherapy window preceding combined
neoadjuvant chemo- and immune therapy in triple-negative breast
cancer: the neoMono trial. Clin Cancer Res. 31:4680–4687. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dugo M, Huang CS, Egle D, Bermejo B,
Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S,
et al: The Immune-related 27-gene signature DetermaIO predicts
response to neoadjuvant atezolizumab plus chemotherapy in
triple-negative breast cancer. Clin Cancer Res. 30:4900–4909. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Balko JM, Licata L, Wang XQ, Dugo M, Huang
CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, et al:
Tumor-specific major histocompatibility-II expression predicts
pathological complete response to atezolizumab combined to
chemotherapy in triple-negative breast cancer. NPJ Breast Cancer.
11:1032025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Blenman KRM, Marczyk M, Karn T, Qing T, Li
X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, et al:
Predictive markers of response to neoadjuvant durvalumab with
nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in
basal-like triple-negative breast cancer. Clin Cancer Res.
28:2587–2597. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bonadio RC, Tarantino P, Testa L, Punie K,
Pernas S, Barrios C, Curigliano G, Tolaney SM and Barroso-Sousa R:
Management of patients with early-stage triple-negative breast
cancer following pembrolizumab-based neoadjuvant therapy: What are
the evidences? Cancer Treat Rev. 110:1024592022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim N, Kim SS, Cho WK, Park W, Chang JH,
Kim YB, Chang AR, Kim TH, Park J, Kim JH, et al: Concurrent versus
sequential adjuvant capecitabine-based chemoradiation in residual
triple-negative breast cancer after preoperative systemic therapy:
A multicenter comparative study. Int J Radiat Oncol Biol Phys.
122:72–83. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Loap P, Loirat D, Berger F, Rodrigues M,
Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L,
Raizonville L, et al: Concurrent olaparib and radiotherapy in
patients with triple-negative breast cancer: The phase 1 Olaparib
and Radiation Therapy for Triple-Negative Breast Cancer trial. JAMA
Oncol. 8:1802–1808. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Loap P, Loirat D, Berger F, Cao K, Ricci
F, Jochem A, Raizonville L, Mosseri V, Fourquet A and Kirova Y:
Combination of Olaparib with radiotherapy for triple-negative
breast cancers: One-year toxicity report of the RADIOPARP Phase I
trial. Int J Cancer. 149:1828–1832. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Colciago RR, Presti D, Giandini C, Rocca
E, Carnevale MG, Cavallo A, Pignoli E, Lobefaro R, Listorti C,
Lozza L, et al: Real world feasibility of combining pembrolizumab
with radiotherapy in early triple negative breast cancer. Discov
Oncol. 16:16332025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
El Fakih A, Loap P, Cabel L, Allali S, Cao
K, Mirabel M, Pierga JY and Kirova Y: Real-world safety of
concurrent pembrolizumab and radiotherapy in triple-negative breast
cancer. Am J Clin Oncol. 49:62–68. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Myers SP, Sevilimedu V, Jones VM, Abuhadra
N, Montagna G, Plitas G, Morrow M and Downs-Canner SM: Impact of
neoadjuvant chemoimmunotherapy on surgical outcomes and time to
radiation in triple-negative breast cancer. Ann Surg Oncol.
31:5180–5188. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lee TH, Kim H, Kim YJ, Park WY, Park W,
Cho WK and Kim N: Implication of pre- and post-radiotherapy ctDNA
dynamics in patients with residual triple-negative breast cancer at
surgery after neoadjuvant chemotherapy: Findings from a prospective
observational study. Cancer Res Treat. 56:531–537. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Turner NC, Swift C, Jenkins B, Kilburn L,
Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek
P, et al: Results of the c-TRAK TN trial: A clinical trial
utilising ctDNA mutation tracking to detect molecular residual
disease and trigger intervention in patients with moderate- and
high-risk early stage triple negative breast cancer. Ann Oncol.
34:200–211. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhang D, Jahanfar S, Rabinowitz JB, Dower
J, Song F, Wu CH, Hu X, Tracy P, Basik M, Medford A, et al: Role of
circulating tumor DNA in early-stage triple-negative breast cancer:
A systematic review and meta-analysis. Breast Cancer Res.
27:382025. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Stecklein SR, Kimler BF, Yoder R,
Schwensen K, Staley JM, Khan QJ, O'Dea AP, Nye LE, Elia M, Heldstab
J, et al: ctDNA and residual cancer burden are prognostic in
triple-negative breast cancer patients with residual disease. NPJ
Breast Cancer. 9:102023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Radovich M, Jiang G, Hancock BA, Chitambar
C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, et
al: Association of circulating tumor DNA and circulating tumor
cells after neoadjuvant chemotherapy with disease recurrence in
patients with triple-negative breast cancer: Preplanned secondary
analysis of the BRE12-158 Randomized clinical trial. JAMA Oncol.
6:1410–1415. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cavallone L, Aguilar-Mahecha A, Lafleur J,
Brousse S, Aldamry M, Roseshter T, Lan C, Alirezaie N, Bareke E,
Majewski J, et al: Prognostic and predictive value of circulating
tumor DNA during neoadjuvant chemotherapy for triple negative
breast cancer. Sci Rep. 10:147042020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Parsons HA, Blewett T, Chu X, Sridhar S,
Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, et al:
Circulating tumor DNA association with residual cancer burden after
neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC
030. Ann Oncol. 34:899–906. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zaikova E, Cheng BYC, Cerda V, Kong E, Lai
D, Lum A, Bates C, den Brok W, Kono T, Bourque S, et al:
Circulating tumour mutation detection in triple-negative breast
cancer as an adjunct to tissue response assessment. NPJ Breast
Cancer. 10:32024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Coakley M, Villacampa G, Sritharan P,
Swift C, Dunne K, Kilburn L, Goddard K, Pipinikas C, Rojas P,
Emmett W, et al: Comparison of circulating tumor DNA assays for
molecular residual disease detection in early-stage triple negative
breast cancer. Clin Cancer Res. 30:895–903. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ademuyiwa FO, Ma CX, Weilbaecher K, Suresh
R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Clifton K,
et al: Detection of circulating tumor DNA using a tissue-free
epigenomic assay is a highly prognostic biomarker in early-stage
triple-negative breast cancer. Clin Cancer Res. 31:2173–2182. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Watkins JA, Irshad S, Grigoriadis A and
Tutt AN: Genomic scars as biomarkers of homologous recombination
deficiency and drug response in breast and ovarian cancers. Breast
Cancer Res. 16:2112014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Villacampa G, Llop-Guevara A, Filmann N,
Herencia-Ropero A, Fasching PA, Karn T, Marmé F, Klare P, Müller V,
Stefek A, et al: RAD51 testing in patients with early HER2-Negative
breast cancer and homologous recombination deficiency: A Post Hoc
analysis of the GeparOLA trial. Clin Cancer Res. 31:808–814. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Pusztai L, Yau C, Wolf DM, Han HS, Du L,
Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, et al:
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative
stage II/III breast cancer: Results from the adaptively randomized
I-SPY2 trial. Cancer Cell. 39:989–998.e5. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Fasching PA, Schmatloch S, Hauke J, Rey J,
Jackisch C, Klare P, Link T, Hanusch C, Huober J, Stefek A, et al:
Neoadjuvant paclitaxel/olaparib in comparison to
paclitaxel/carboplatin in patients with HER2-negative breast cancer
and HRD - long-term survival of the GeparOLA study. Clin Cancer
Res. 31:1596–1604. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sinn BV, Sychra K, Untch M, Karn T, van
Mackelenbergh M, Huober J, Schmitt W, Marmé F, Schem C, Solbach C,
et al: On-treatment biopsies to predict response to neoadjuvant
chemotherapy for breast cancer. Breast Cancer Res. 26:1382024.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Leon-Ferre RA, Dimitroff K, Yau C,
Giridhar KV, Mukhtar R, Hirst G, Hylton N, Perlmutter J, DeMichele
A, Yee D, et al: Combined prognostic impact of initial clinical
stage and residual cancer burden after neoadjuvant systemic therapy
in triple-negative and HER2-positive breast cancer: An analysis of
the I-SPY2 randomized clinical trial. Breast Cancer Res.
27:1152025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Martín M, Stecklein SR, Gluz O, Villacampa
G, Monte-Millán M, Nitz U, Cobo S, Christgen M, Brasó-Maristany F,
Álvarez EL, et al: TNBC-DX genomic test in early-stage
triple-negative breast cancer treated with neoadjuvant taxane-based
therapy. Ann Oncol. 36:158–171. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang Q, Yu Y, Wang C, Jiang Z, Li J, Li X,
Huang X, Song Y, Li Z, Tang S and Song C: Heterogeneity of tertiary
lymphoid structures predicts the response to neoadjuvant therapy
and immune microenvironment characteristics in triple-negative
breast cancer. Br J Cancer. 132:295–310. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Mayer IA, Zhao F, Arteaga CL, Symmans WF,
Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower
DF, et al: Randomized phase III postoperative trial of
platinum-based chemotherapy versus capecitabine in patients with
residual triple-negative breast cancer following neoadjuvant
chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 39:2539–2551. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Agostinetto E, Jacobs F, Debien V, De
Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E and Buisseret
L: Post-neoadjuvant treatment strategies for patients with early
breast cancer. Cancers (Basel). 14:54672022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Tolaney SM, DeMichele A, Takano T, Rugo
HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W,
et al: OptimICE-RD: Sacituzumab govitecan plus pembrolizumab versus
pembrolizumab (± capecitabine) for residual triple-negative breast
cancer. Future Oncol. 20:2343–2355. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Graciano N, López L, Rodriguez CA, Montoya
K and Cortés J: Survival impact of adjuvant capecitabine in
triple-negative breast cancer Latin American patients with residual
disease: A real-world study. Breast Cancer Res Treat. 214:265–275.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Beyerlin K, Jimenez R, Zangardi M, Fell
GG, Edmonds C, Johnson A, Bossuyt V, Specht M, Mulvey TM, Moy B, et
al: The adjuvant use of capecitabine for residual disease following
pre-operative chemotherapy for breast cancer: Challenges applying
CREATE-X to a US population. J Oncol Pharm Pract. 27:1883–1890.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Asleh K, Lluch A, Goytain A, Barrios C,
Wang XQ, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, et
al: Triple-negative PAM50 non-basal breast cancer subtype predicts
benefit from extended adjuvant capecitabine. Clin Cancer Res.
29:389–400. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lynce F, Mainor C, Donahue RN, Geng X,
Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, et al:
Adjuvant nivolumab, capecitabine or the combination in patients
with residual triple-negative breast cancer: The OXEL randomized
phase II study. Nat Commun. 15:26912024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lee J, Ahn HK, Lee KH, Jung KH, Park YH,
Sim SH, Kim MH, Kim JH, Kim JH, Lee KE, et al: Randomized, phase II
trial to evaluate the efficacy and safety of atezolizumab plus
capecitabine adjuvant therapy compared to capecitabine monotherapy
for triple receptor-negative breast cancer with residual invasive
cancer after neoadjuvant chemotherapy (MIRINAE trial,
KCSG-BR18-21). BMC Cancer. 25:12952025. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Im SA, Park K, Koh J, Park C, Jung KH, Lee
J, Ahn HK, Lee A, Sim SH, Kim MH, et al: Genomic and transcriptomic
analyses of residual invasive triple-negative breast cancer after
neoadjuvant chemotherapy in the prospective MIRINAE trial (a
randomized phase II trial of adjuvant atezolizumab plus
capecitabine compared to capecitabine; KCSG-BR18-21). ESMO Open.
10:1058042025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Conte PF, Dieci MV, Bisagni G, Schmid P,
Zambelli A, Piacentini F, De Laurentiis M, Favaretto AG, Tamberi S,
Bianchi GV, et al: A-BRAVE trial: A phase III randomized trial with
anti-PD-L1 avelumab in high-risk triple-negative early breast
cancer patients. Ann Oncol. 36:1492–1502. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ignatiadis M, Bailey A, McArthur H,
El-Abed S, de Azambuja E, Metzger O, Chui SY, Dieterich M, Perretti
T, Shearer-Kang E, et al: Adjuvant atezolizumab for early
triple-negative breast cancer: The ALEXANDRA/IMpassion030
randomized clinical trial. JAMA. 333:1150–1160. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
SWOG Cancer Research Network, .
S1418/BR006: A randomized phase III trial to evaluate efficacy and
safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple
receptor-negative breast cancer with >/=1 cm residual invasive
cancer or positive lymph nodes (ypN1mi, ypN1-3) after neoadjuvant
chemotherapy. https://www.swog.org/clinical-trials/s1418br006June
15–2026
|
|
98
|
Bardia A, Hurvitz SA, Tolaney SM, Loirat
D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak
AB, et al: Sacituzumab govitecan in metastatic triple-negative
breast cancer. N Engl J Med. 384:1529–1541. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Okajima D, Yasuda S, Maejima T, Karibe T,
Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, et al:
Datopotamab deruxtecan, a novel TROP2-directed antibody-drug
conjugate, demonstrates potent antitumor activity by efficient drug
delivery to tumor cells. Mol Cancer Ther. 20:2329–2340. 2021.
View Article : Google Scholar : PubMed/NCBI
|
